World Class Research

As the largest private funder of pancreatic cancer research, we are relentlessly focused on improving patient outcomes and we are making progress every day. Thanks to separate funding to support administrative expenses, 100 percent of every donation goes directly to research.

Navigating Pancreatic Cancer

We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.

Patient Checklist


August 1, 2018 ladmin

As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]


Clinical Trials Finder

July 30, 2018 ladmin

If you have been diagnosed with pancreatic cancer, a clinical trial may be your best treatment option. Many clinical trials are underway for patients in all stages of the disease and may involve new combinations of currently available drugs or new drugs that have worked in other cancers. No matter where you are in your journey, we encourage you to learn more about clinical trials.

Lets Win! Pancreatic Cancer

Let’s Win! Pancreatic Cancer

July 20, 2018 ladmin

LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]

Pancreatic Cancer Connections

July 7, 2018 ladmin

Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery.

Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

Lustgarten News

View All Articles

Pancakes for a Purpose

The event’s founders did a fantastic job during their segment on WBTV News to talk about their 9th annual Pancakes for a Purpose event on Saturday, February 23rd at Blackfinn Ameripub – Ballantyne in Charlotte, North Carolina.

The event is in memory of Dave Anstadt and John Bradley, who both lost their fight with pancreatic cancer. All proceeds will benefit the Foundation.

This year, raffle items include a wine tasting at Total Wine, golf at Ballantyne Country Club, and gift cards to Sugar Creek and Oriental Trading, among many other prizes. Purchase tickets now!

Learn More

Stand Up To Cancer Summit

Leading Cancer Researchers Coming Together to Collaborate

Stand Up To Cancer (SU2C) hosted its 9th annual Scientific Summit in Santa Monica, CA where all of its funded researchers gather to provide updates, new grants are awarded and proposals are reviewed.  It’s a dynamic and inspiriting three days where more than 300 top scientists come together to discuss breakthroughs and updates in cancer research.

The Lustgarten Foundation is proud to be a part of this important meeting. Since 2012, we have built a robust and illustrious collaboration with SU2C, jointly funding 209 investigators across 31 leading research centers in both the United States and the United Kingdom, which is now the Pancreatic Cancer Collective.

The Collective scientists — comprised of 14 teams (three dream teams,  nine research teams and two convergence teams) are investigating pancreatic cancer in the field of immunotherapy, early detection, interception and new therapies. Two invited speakers, Dr. Brian Wolpin, head of our dedicated research lab at Dana Farber, and Dr. David Ryan, medical oncologist at Mass General Hospital and leader of one of the research teams, shared their novel data about a model risk for pancreatic cancer and the first pancreatic cancer clinical trial enrolling patients to be treated at home.

Additionally, during the summit, the Collective grants review committee evaluated proposals for Computational Approaches to Identifying High-Risk Pancreatic Cancer Populations with the goal of awarding two new grants.  The funding will help to develop tools to identify individuals in the general population who are at high risk for pancreatic cancer far earlier than they would otherwise be diagnosed, using information from existing health records.

 One Team was selected to identify high risk cohorts  through molecular and genetic data identifying new and accessible ways to identify high risk individuals and the other team will identify  high risk cohorts through real world data. The winners of these important new grants will be announced in the spring of 2019. 

 In case you missed it, check out the Facebook live from the Summit that was hosted by our chief scientist Dr. David Tuveson,

Learn More

Fourth Lab Opens

Lustgarten Foundation Opens Laboratory at Johns Hopkins Focused on Early Detection and Genetics of Pancreatic Cancer.

The Lustgarten Foundation announced today the opening of its fourth dedicated pancreatic cancer research laboratory at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. The laboratory at Johns Hopkins University will join three other Lustgarten Foundation dedicated pancreatic cancer research laboratories, which include Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, and Massachusetts Institute of Technology.

Led by Dr. Bert Vogelstein, one of the most cited scientists and Director of the Ludwig Center Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center, the Lustgarten Laboratory at Johns Hopkins will leverage its expertise in early detection to intercept pancreatic cancer at an earlier stage when patients may be surgical candidates and will develop novel therapeutic approaches to treat pancreatic cancer based on genetic alterations.

Learn More

Pancreatic Cancer News

View All Articles

Could Losing Weight Lower My Risk of Cancer?

12. 2. 19 ladmin

ACCORDING TO THE LATEST data released by the American Cancer Society, cancer deaths have declined by more than one-quarter (27 percent) over a 25-year span, from 1991 to 2016. But countering that trend, obesity-related cancer is increasing. Previous research indicates that, as noted in the ACS’ Cancer Facts & Figures 2019 report: “An estimated 5% […]

What Are the First Signs of Pancreatic Cancer

8. 2. 19 ladmin

PANCREATIC CANCER IS SO difficult to treat in large part because it often isn’t discovered until the disease has spread to other parts of the body. That’s because in many cases there are no signs or symptoms until the cancer has reached an advanced stage. Even when there are early signs and symptoms, they are […]

Tackling tumor scar tissue could be key to treating pancreatic cancer

8. 2. 19 ladmin

The research, led by Queen Mary University of London, The Institute of Cancer Research, London, Beaujon University Hospital (INSERM), Paris, and Barts Health NHS Trust, could lead to tailor-made treatments, including immunotherapies, which target the powerful scar tissue wall that protects the cancer and makes it such a difficult disease to treat. Co-lead researcher Professor […]

BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

4. 2. 19 ladmin

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040, for the treatment of pancreatic cancer. “Orphan Drug Designation in pancreatic cancer is a very important milestone in the development plan of […]

Some Cancers Are Rising in Millennials. Obesity Might Be Why

4. 2. 19 ladmin

The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Obesity rates have been […]

New combination blood test for pancreatic cancer may catch disease earlier

17. 1. 19 ladmin

A new approach to pancreatic cancer screening may help doctors detect the disease in people at high risk before it reaches more advanced and difficult-to treat stages. A team led by Van Andel Research Institute (VARI) scientists has developed a new, simple blood test that, when combined with an existing test, detects nearly 70 percent […]

Antihypertension drug losartan may improve treatment of ovarian cancer

15. 1. 19 ladmin

A new study from a Massachusetts General Hospital (MGH) research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer. Previous research from the same team identified a similar effect for losartan in animal models of breast and pancreatic cancer, […]

VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance

11. 1. 19 ladmin

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers. The University of Texas MD Anderson Cancer Center research team found overexpression of the immune checkpoint VISTA on immune cells, especially macrophages, that […]